| Biomarker ID | 410 |
| PMID | 19131636 |
| Year | 2009 |
| Biomarker | Methylation Status of RARB2 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Serum |
| Subjects | Humans |
| Regulation | Methylated in Stage IV PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Non-small cell lung cancer,Vitamin A and carotenoid metabolism,Nuclear receptor transcription pathway,Nuclear receptors,Small cell lung cancer |
| Experiment | PCa stage I-III VS PCa Stage IV |
| Type of Biomarker | Prognostic |
| Cohort | 40 healthy donors and 83 patients were analysed for the study. Out of 83 patients, 25 were identified from Stage (I-III) and 58 were categorised into stage IV. 0 out of 25 showed methylation in RARB. 10 out of 58 showed methylation in RARB. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.027 |
| Method Used | methylation-specific PCR assay |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | RARB2 |